<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cain, Lauren E</style></author><author><style face="normal" font="default" size="100%">Phillips, Andrew</style></author><author><style face="normal" font="default" size="100%">Olson, Ashley</style></author><author><style face="normal" font="default" size="100%">Sabin, Caroline</style></author><author><style face="normal" font="default" size="100%">Jose, Sophie</style></author><author><style face="normal" font="default" size="100%">Justice, Amy</style></author><author><style face="normal" font="default" size="100%">Tate, Janet</style></author><author><style face="normal" font="default" size="100%">Logan, Roger</style></author><author><style face="normal" font="default" size="100%">Robins, James M</style></author><author><style face="normal" font="default" size="100%">Sterne, Jonathan A C</style></author><author><style face="normal" font="default" size="100%">van Sighem, Ard</style></author><author><style face="normal" font="default" size="100%">Reiss, Peter</style></author><author><style face="normal" font="default" size="100%">Young, James</style></author><author><style face="normal" font="default" size="100%">Fehr, Jan</style></author><author><style face="normal" font="default" size="100%">Touloumi, Giota</style></author><author><style face="normal" font="default" size="100%">Paparizos, Vasilis</style></author><author><style face="normal" font="default" size="100%">Esteve, Anna</style></author><author><style face="normal" font="default" size="100%">Casabona, Jordi</style></author><author><style face="normal" font="default" size="100%">Monge, Susana</style></author><author><style face="normal" font="default" size="100%">Moreno, Santiago</style></author><author><style face="normal" font="default" size="100%">Seng, Rémonie</style></author><author><style face="normal" font="default" size="100%">Meyer, Laurence</style></author><author><style face="normal" font="default" size="100%">Pérez-Hoyos, Santiago</style></author><author><style face="normal" font="default" size="100%">Muga, Roberto</style></author><author><style face="normal" font="default" size="100%">Dabis, François</style></author><author><style face="normal" font="default" size="100%">Vandenhende, Marie-Anne</style></author><author><style face="normal" font="default" size="100%">Abgrall, Sophie</style></author><author><style face="normal" font="default" size="100%">Costagliola, Dominique</style></author><author><style face="normal" font="default" size="100%">Hernán, Miguel A</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">HIV-CAUSAL Collaboration</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Infect Dis</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Clin. Infect. Dis.</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adolescent</style></keyword><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">Anti-HIV Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Antiretroviral Therapy, Highly Active</style></keyword><keyword><style  face="normal" font="default" size="100%">Atazanavir Sulfate</style></keyword><keyword><style  face="normal" font="default" size="100%">CD4 Lymphocyte Count</style></keyword><keyword><style  face="normal" font="default" size="100%">Cohort Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Cooperative Behavior</style></keyword><keyword><style  face="normal" font="default" size="100%">Developed Countries</style></keyword><keyword><style  face="normal" font="default" size="100%">Europe</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">HIV Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Lopinavir</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Middle Aged</style></keyword><keyword><style  face="normal" font="default" size="100%">Prospective Studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Treatment Outcome</style></keyword><keyword><style  face="normal" font="default" size="100%">United States</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral Load</style></keyword><keyword><style  face="normal" font="default" size="100%">Young Adult</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 Apr 15</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">60</style></volume><pages><style face="normal" font="default" size="100%">1262-8</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">BACKGROUND: Current clinical guidelines consider regimens consisting of either ritonavir-boosted atazanavir or ritonavir-boosted lopinavir and a nucleoside reverse transcriptase inhibitor (NRTI) backbone among their recommended and alternative first-line antiretroviral regimens. However, these guidelines are based on limited evidence from randomized clinical trials and clinical experience.

METHODS: We compared these regimens with respect to clinical, immunologic, and virologic outcomes using data from prospective studies of human immunodeficiency virus (HIV)-infected individuals in Europe and the United States in the HIV-CAUSAL Collaboration, 2004-2013. Antiretroviral therapy-naive and AIDS-free individuals were followed from the time they started a lopinavir or an atazanavir regimen. We estimated the 'intention-to-treat' effect for atazanavir vs lopinavir regimens on each of the outcomes.

RESULTS: A total of 6668 individuals started a lopinavir regimen (213 deaths, 457 AIDS-defining illnesses or deaths), and 4301 individuals started an atazanavir regimen (83 deaths, 157 AIDS-defining illnesses or deaths). The adjusted intention-to-treat hazard ratios for atazanavir vs lopinavir regimens were 0.70 (95% confidence interval [CI], .53-.91) for death, 0.67 (95% CI, .55-.82) for AIDS-defining illness or death, and 0.91 (95% CI, .84-.99) for virologic failure at 12 months. The mean 12-month increase in CD4 count was 8.15 (95% CI, -.13 to 16.43) cells/µL higher in the atazanavir group. Estimates differed by NRTI backbone.

CONCLUSIONS: Our estimates are consistent with a lower mortality, a lower incidence of AIDS-defining illness, a greater 12-month increase in CD4 cell count, and a smaller risk of virologic failure at 12 months for atazanavir compared with lopinavir regimens.</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/25567330?dopt=Abstract</style></custom1></record></records></xml>